SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 8 of 16
Word Count: 1436
Character Count: 8967

Document Content:

of each closing on ELOC Shares under the ELOC Purchase Agreement (except for representations and warranties specifically made as of a particular date). ● The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the ELOC Purchase Agreement to be performed, satisfied or complied with by the Company, including but not limited to the delivery of the ELOC Shares in accordance with the ELOC Purchase Agreement. ● There must not be a statute, rule, regulation, executive order, decree, ruling or injunction that has been enacted, entered, promulgated or adopted by any court or governmental authority of competent jurisdiction that prohibits or directly and materially adversely affects any of the transactions contemplated by the ELOC Purchase Agreement, or any proceeding that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by the ELOC Purchase Agreement.

●	There must not be an event
that has had or is reasonably likely to have a material adverse effect on the Company since the date the Company filed its most recent
report with the SEC.

●	Trading of the common stock
must not have been suspended by the SEC, Nasdaq, or FINRA, or otherwise halted for any reason, and the common stock must not have been
delisted from Nasdaq.

●	The number of ELOC Shares to
be purchased by the Selling Stockholder, combined with the number of shares of common stock then owned by the Selling Stockholder, must
not exceed the Beneficial Ownership Limitation (defined herein).

●	The common stock must not be
deemed a “penny stock” as defined in SEC Rule 240.3a51-1.

●	The Company must not know of
any event more likely than not to have the effect of causing the Registration Statement to be suspended or otherwise ineffective.

●	The issuance of the ELOC Shares
must not violate the stockholder approval requirements of Nasdaq.

●	On the date of delivery of
each Put Notice, the Selling Stockholder must have received a closing certificate executed by an executive officer of the Company stating
that all conditions to such closing have been satisfied as of the date of the certificate.

●	The common stock must be eligible
for Deposit Withdrawal at Custodian and not subject to a “DTC chill.”

●	All reports, schedules, registrations,
forms, statements, information and other documents required to have been filed by the Company with the SEC pursuant to the reporting
requirements of the Exchange Act must have been filed with the SEC within the applicable time periods prescribed for such filings under
the Exchange Act.

●	The Company must have reserved
the Required Minimum (as defined in the ELOC Purchase Agreement) for the Selling Stockholder’s benefit under the ELOC Purchase
Agreement and the Company must have satisfied the reserve requirements with respect to all other contracts between the Company and the
Selling Stockholder.

●	The lowest traded price of
the common stock in the ten (10) trading days immediately preceding the respective Put Date must exceed $0.01 per share.

●	Bankruptcy, insolvency, reorganization
or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief
of debtors must not have been instituted by or against the Company or any subsidiary of the Company, and the Company must not have knowledge
of any event more likely than not to have the effect of causing such a proceeding to arise.

Limitation on Sales

At any given time of any sale
by us to the Selling Stockholder, we may not sell, and the Selling Stockholder may not purchase, ELOC Shares that would result in the
Selling Stockholder beneficially owning more than the 4.99% of the number of shares of common stock outstanding immediately after giving
effect to the issuance of shares of common stock issuable pursuant to a Put Notice (the “Beneficial Ownership Limitation”).
Additionally, the Company must obtain stockholder approval to issue an aggregate number of shares of common stock to the Selling Stockholder
under the ELOC Purchase Agreement, in excess of the Exchange Cap prior to delivering any Put Notice.

Commitment Fee

As consideration for the Selling
Stockholder’s execution and delivery of the ELOC Purchase Agreement, the Company issued to the Selling Stockholder the Warrant for
the purchase of 1,540,000 shares of the common stock at an exercise price of $0.01 per share, subject to adjustment. Under the Warrant,
the Selling Stockholder may exercise the Warrant during the period commencing on May 8, 2026 and ending on 5:00 p.m. eastern standard
time on the date that is five (5) years after May 8, 2026. In addition, the Company will pay up to $20,000.00 to the Selling Stockholder’s
legal counsel for the Selling Stockholder’s expenses relating to the preparation of the ELOC Purchase Agreement.

Registration of Shares

In connection with our entry
into the ELOC Purchase Agreement we also entered into a registration rights agreement with the Selling Stockholder (the “Registration
Rights Agreement”). Under the Registration Rights Agreement, we are obligated to file with the SEC a registration statement
for the resale by the Selling Stockholder of the ELOC Shares and the Warrant Shares within thirty (30) days of the execution of the ELOC
Purchase Agreement, and to file one or more additional registration statements if necessary. The Registration Statement is being filed
in order to satisfy our obligations under the ELOC Purchase Agreement and the Registration Rights Agreement related to registering for
resale the ELOC Shares and the Warrant Shares.

Once this Registration Statement
is declared effective by the SEC, if it becomes necessary for us to issue and sell to the Selling Stockholder a greater number of shares
of our common stock than are registered for resale under this Registration Statement, we will be required to file one or more additional
registration statements with the SEC to register the resale of such additional shares under the Securities Act. Each such registration
statement would need to be declared effective by the SEC before we may elect to sell any additional shares of our common stock to the
Selling Stockholder under the ELOC Purchase Agreement.

Termination of the ELOC Purchase Agreement

Unless earlier terminated as
provided in the ELOC Purchase Agreement, the ELOC Purchase Agreement will terminate automatically at the end of the Commitment Period.
The “Commitment Period” commences on May 8, 2026 and ends on the earliest to occur of: (i) the date on which the Selling Stockholder
has purchased ELOC Shares equal to the $36,000,000 maximum commitment amount, (ii) twenty-four (24) months after May 8, 2026, (iii) written
notice of termination by the Company to the Selling Stockholder (subject to certain limitations if the Selling Stockholder then holds
ELOC Shares), (iv) this Registration Statement is no longer effective after the initial effective date of this Registration Statement,
and (v) the occurrence of certain bankruptcy or insolvency-related events.

Limitation on Equity Line of Credit and Variable
Rate Transactions

Pursuant to the ELOC Purchase
Agreement, until the later of (i) twenty-four (24) months from May 8, 2026 or (ii) the date the ELOC Purchase Agreement is no longer in
effect, the Company agreed that it will not, without the prior written consent of the Selling Stockholder, enter into any other “Equity
Line of Credit” (which is generally defined as any transaction involving a written agreement between the Company and an investor
or underwriter whereby the Company has the right to “put” its securities to such investor or underwriter over an agreed period
of time and at an agreed price or price formula).

So long as the ELOC Purchase
Agreement remains in effect, the Company also agreed that it will not, without the prior written consent of the Selling Stockholder, enter
into any “Variable Rate Transaction” (as defined in the ELOC Purchase Agreement) with any other party, unless the Company
first provides the Selling Stockholder with (i) a term sheet detailing the proposed Variable Rate Transaction (including the dollar amount,
price and other terms upon which the securities are to be issued, sold or exchanged) and (ii) a three (3) trading day period for the Selling
Stockholder to elect to consummate such Variable Rate Transaction with the Company. If the Selling Stockholder elects not to consummate
such Variable Rate Transaction with the Company, then the references to “95%” in the definitions of both the Initial Purchase
Price and the Market Price under the ELOC Purchase Agreement are automatically amended to “90%”. The ELOC Purchase Agreement
also provides that an Equity Line of Credit and an at-the-market offering under the Company’s existing sales agreement are not deemed
to be Variable Rate Transactions.

Dilutive Effect